Demographic characteristics and clinical and laboratory features of cohort (n = 513).
| Participants With Any NPSLE Feature, n = 201 | Participants With No NPSLE Features, n = 312 | P | |
|---|---|---|---|
| Female sex | 166 (83) | 258 (83) | > 0.99 |
| Age at SLE diagnosis, yrs | 14.2 (11.7–15.7) | 13.5 (11.2–15.5) | 0.17 |
| Duration of follow-up, yrs | 5.2 (3.0–7.8) | 4.5 (2.5–7.3) | 0.12 |
| Inferred ancestry | < 0.01 | ||
| European | 76 (38) | 81 (26) | |
| Admixeda | 51 (25) | 69 (22) | |
| East Asian | 41 (20) | 102 (33) | |
| African | 17 (8) | 37 (12) | |
| South Asian | 16 (8) | 23 (7) | |
| Clinical features (ever) | |||
| Malar rash | 170 (85) | 236 (76) | 0.02 |
| Oral or nasal ulcers | 96 (48) | 114 (37) | 0.02 |
| Arthritis | 161 (80) | 206 (66) | < 0.01 |
| Serositisb | 36 (18) | 50 (16) | 0.66 |
| Myositis | 17 (8) | 15 (5) | 0.14 |
| LN (any) | 80 (40) | 133 (43) | 0.59 |
| Mesangial LN | 11 (5) | 12 (4) | 0.52 |
| Proliferative LN | 61 (30) | 103 (33) | 0.59 |
| Membranous LN | 19 (9) | 47 (15) | 0.09 |
| Mixed proliferative/membranous LN | 8 (4) | 25 (8) | 0.10 |
| SLE laboratory features | |||
| Thrombocytopenia | 60 (30) | 90 (29) | 0.88 |
| Lymphopenia | 161 (81) | 213 (68) | < 0.01 |
| Coombs-positive hemolytic anemia | 79 (39) | 94 (30) | 0.04 |
| Specific autoantibodies | |||
| Anti-dsDNA | 134 (67) | 229 (73) | 0.12 |
| Anti-Sm | 89 (44) | 117 (38) | 0.15 |
| Anti-RNP | 95 (47) | 136 (44) | 0.47 |
| Anti-Ro | 82 (41) | 111 (36) | 0.27 |
| Anti-La | 27 (13) | 64 (21) | 0.05 |
| LAC and/or aCL | 106 (53) | 132 (42) | 0.03 |
| LAC | 40 (20) | 39 (13) | 0.03 |
| aCL | 95 (47) | 115 (37) | 0.02 |
Values are expressed as n (%) or median (IQR).
↵a Admixed category includes participants with < 80% single ancestral proportion as well as those of Amerindian (n = 15) ancestral proportion due to sample size restrictions.
↵b Pericarditis and/or pleuritis. aCL: anticardiolipin antibody; LAC: lupus anticoagulant; LN: lupus nephritis; NPSLE: neuropsychiatric SLE; SLE: systemic lupus erythematosus.